Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1983 Jun;80(11):3485–3488. doi: 10.1073/pnas.80.11.3485

Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.

M G de Quijada, T W Redding, D H Coy, I Torres-Aleman, A V Schally
PMCID: PMC394069  PMID: 6134284

Abstract

We investigated the effects of [D-Trp6]LH-RH [agonistic analog of luteinizing hormone-releasing hormone (LH-RH)], N-Ac-[D-p-Cl-Phe1,2,D-Trp3,D-Phe6,D-Ala10]LH-RH (antagonistic analog), and [D-5-methoxy-Trp8]somatostatin (somatostatin analog) on the growth of the prolactin and corticotropin-secreting pituitary tumor 7315a in female Buffalo rats. Chronic administration of [D-Trp6]LH-RH in a dose of 25 micrograms/day, starting 18 days after inoculation with the tumor, inhibited the growth of the pituitary tumor. Tumor weight and volume also were reduced when this agonist was administered 3 days after inoculation. The antagonistic LH-RH analog, injected in a dose of 50-100 micrograms for 14-24 days, also significantly inhibited the growth of pituitary tumor. Chronic administration of the somatostatin analog in a dose of 25 micrograms twice a day likewise decreased tumor weights in comparison with controls. The inhibition of pituitary tumor growth by LH-RH agonist, LH-RH antagonist, and somatostatin analog was accompanied by a decrease in serum prolactin levels. It was concluded that LH-RH agonist, LH-RH antagonist, and somatostatin analog can inhibit the growth of estrogen-dependent prolactin/corticotropin-secreting pituitary tumor in rats.

Full text

PDF
3487

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergquist C., Nillius S. J., Bergh T., Skarin G., Wide L. Inhibitory effects on gonadotrophin secretion and gonadal function in men during chronic treatment with a potent stimulatory luteinizing hormone-releasing hormone analogue. Acta Endocrinol (Copenh) 1979 Aug;91(4):601–608. doi: 10.1530/acta.0.0910601. [DOI] [PubMed] [Google Scholar]
  2. Bergquist C., Nillius S. J., Wide L. Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent. Lancet. 1979 Aug 4;2(8136):215–217. doi: 10.1016/s0140-6736(79)90235-6. [DOI] [PubMed] [Google Scholar]
  3. Besser G. M., Mortimer C. H., Carr D., Schally A. V., Coy D. H., Evered D., Kastin A. J., Tunbridge W. M., Thorner M. O., Hall R. Growth hormone release inhibiting hormone in acromegaly. Br Med J. 1974 Mar 2;1(5904):352–355. doi: 10.1136/bmj.1.5904.352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cusan L., Auclair C., Belanger A., Ferland L., Kelly P. A., Seguin C., Labrie F. Inhibitory effects of long term treatment with a luteinizing hormone-releasing hormone agonist on the pituitary-gonadal axis in male and female rats. Endocrinology. 1979 May;104(5):1369–1376. doi: 10.1210/endo-104-5-1369. [DOI] [PubMed] [Google Scholar]
  5. Danguy A., Legros N., Heuson-Stiennon J. A., Pasteels J. L., Atassi G., Heuson J. C. Effects of a gonadotropin-releasing hormone (GnRH) analogue (A-43818) on 7, 12- dimethylbenz (a)anthracene-induced rat mammary tumors. Histological and endocrine studies. Eur J Cancer. 1977 Oct;13(10):1089–1094. doi: 10.1016/0014-2964(77)90005-6. [DOI] [PubMed] [Google Scholar]
  6. DeSombre E. R., Johnson E. S., White W. F. Regression of rat mammary tumors effected by a gonadoliberin analog. Cancer Res. 1976 Oct;36(10):3830–3833. [PubMed] [Google Scholar]
  7. Erchegyi J., Coy D. H., Nekola M. V., Coy E. J., Schally A. V., Mezo I., Teplan I. Luteinizing hormone-releasing hormone analogs with increased anti-ovulatory activity. Biochem Biophys Res Commun. 1981 Jun 16;100(3):915–920. doi: 10.1016/0006-291x(81)91910-0. [DOI] [PubMed] [Google Scholar]
  8. Hall R., Besser G. M., Schally A. V., Coy D. H., Evered D., Goldie D. J., Kastin A. J., McNeilly A. S., Mortimer C. H., Phenekos C. Action of growth-hormone-release inhibitory hormone in healthy men and in acromegaly. Lancet. 1973 Sep 15;2(7829):581–584. doi: 10.1016/s0140-6736(73)92413-6. [DOI] [PubMed] [Google Scholar]
  9. Hirst B. H., Shaw B., Meyers C. A., Coy D. H. Structure-activity studies with somatostatin: the role of tryptophan in position 8. Regul Pept. 1980 Oct;1(2):97–113. doi: 10.1016/0167-0115(80)90014-2. [DOI] [PubMed] [Google Scholar]
  10. Janik P., Briand P., Hartmann N. R. The effect of estrone-progesterone treatment on cell proliferation kinetics of hormone-dependent GR mouse mammary tumors. Cancer Res. 1975 Dec;35(12):3698–3704. [PubMed] [Google Scholar]
  11. Lamberts S. W., Uitterlinden P., Zuiderwijk-Roest J. M., Bons-van Evelingen E. G., de Jong F. H. Effects of a luteinizing hormone-releasing hormone analog and tamoxifen on the growth of an estrogen-induced prolactin-secreting rat pituitary tumor and its influence on pituitary gonadotropins. Endocrinology. 1981 May;108(5):1878–1884. doi: 10.1210/endo-108-5-1878. [DOI] [PubMed] [Google Scholar]
  12. Redding T. W., Coy D. H., Schally A. V. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1982 Feb;79(4):1273–1276. doi: 10.1073/pnas.79.4.1273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Redding T. W., Schally A. V. Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6509–6512. doi: 10.1073/pnas.78.10.6509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rodriguez-Arnao M. D., Gomez-Pan A., Rainbow S. J., Woodhead S., Comaru-Schally A. M., Schally A. V., Meyers C. A., Coy D. H., Hall R. Effects of prosomatostatin on growth hormone and prolactin response to arginine in man. Comparison with somatostatin. Lancet. 1981 Feb 14;1(8216):353–356. doi: 10.1016/s0140-6736(81)91673-1. [DOI] [PubMed] [Google Scholar]
  15. Sandow J., Von Rechenberg W., Jerzabek G., Stoll W. Pituitary gonadotropin inhibition by a highly active analog of luteinizing hormone-releasing hormone. Fertil Steril. 1978 Aug;30(2):205–209. doi: 10.1016/s0015-0282(16)43461-8. [DOI] [PubMed] [Google Scholar]
  16. Schally A. V., Coy D. H., Meyers C. A. Hypothalamic regulatory hormones. Annu Rev Biochem. 1978;47:89–128. doi: 10.1146/annurev.bi.47.070178.000513. [DOI] [PubMed] [Google Scholar]
  17. Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Tolis G., Mehta A., Comaru-Schally A. M., Schally A. V. Suppression of androgen production by D-tryptophan-6-luteinizing hormone-releasing hormone in man. J Clin Invest. 1981 Sep;68(3):819–822. doi: 10.1172/JCI110320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Vilchez-Martinez J. A., Pedroza E., Arimura A., Schally A. V. Paradoxical effects of D-Trp6-luteinizing hormone-releasing hormone on the hypothalamic-pituitary-gonadal axis in immature female rats. Fertil Steril. 1979 Jun;31(6):677–682. doi: 10.1016/s0015-0282(16)44061-6. [DOI] [PubMed] [Google Scholar]
  20. Zarate A., Canales E. S., Sthory I., Coy D. H., Comaru-Schally A. M., Schally A. V. Anovulatory effect of a LHRH antagonist in women. Contraception. 1981 Sep;24(3):315–320. doi: 10.1016/0010-7824(81)90044-5. [DOI] [PubMed] [Google Scholar]
  21. de Quijada M., Timmermans H. A., Lamberts S. W. Tamoxifen suppresses both the growth of prolactin-secreting pituitary tumours and normal prolactin synthesis in the rat. J Endocrinol. 1980 Jul;86(1):109–116. doi: 10.1677/joe.0.0860109. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES